Glenmark Pharmaceuticals Limited Profit Margin

The latest profit margin for GLENMARK.BO is 10.14% as of June 2026. That compares with 5.66% in the prior-year period — up 79.0% year over year. That is below the sector sector average of 13.78%. Investors often review this figure alongside Glenmark Pharmaceuticals Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, GLENMARK.BO's profit margin moved from 5.66% to 10.14% — a 79.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Glenmark Pharmaceuticals Limited's valuation or profitability profile.

Against its sector companies, GLENMARK.BO currently prints 10.14% for profit margin, while the sector average sits near 13.78%. That is roughly 26.4% below the sector mean. Large gaps often invite a closer look at Glenmark Pharmaceuticals Limited's growth, margins, and balance sheet.

Profit Margin shows how effectively Glenmark Pharmaceuticals Limited converts resources into returns. At 10.14%, GLENMARK.BO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 5.66% in the prior-year period — up 79.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GLENMARK.BO's profit margin (10.14%), review year-over-year change from 5.66%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.